Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Jean A Boutin. (2016) Quinone reductase 2 as a promising target of melatonin therapeutic actions. Expert Opinion on Therapeutic Targets 20:3, pages 303-317.
Read now
Read now
Dorra Dridi, Amina Zouiten & Hedi Ben Mansour. (2014) Depression: chronophysiology and chronotherapy. Biological Rhythm Research 45:1, pages 77-91.
Read now
Read now
Emiliano Ricardo Vasconcelos Rios, Edith Teles Venâncio, Nayrton Flávio Moura Rocha, David John Woods, Silvania Vasconcelos, Danielle Macedo, Francisca Cléa Florenço de Sousa & Marta Maria de França Fonteles. (2010) Melatonin: Pharmacological Aspects and Clinical Trends. International Journal of Neuroscience 120:9, pages 583-590.
Read now
Read now
Francesco Portaluppi. (2007) Consistency and Accuracy of the Medical Subject Headings® Thesaurus for Electronic Indexing and Retrieval of Chronobiologic References. Chronobiology International 24:6, pages 1213-1229.
Read now
Read now
Articles from other publishers (34)
Busra Dincer, Gizem Yildiztekin & Irfan Cinar. (2023) Unlocking Synergistic Potential: Agomelatine Enhances the Chemotherapeutic Effect of Paclitaxel in Breast Cancer Cell Through MT1 Melatonin Receptors and ER‐alpha Axis. Chemistry & Biodiversity 20:10.
Crossref
Crossref
Eyup Dil, Atilla Topcu, Tolga Mercantepe, Levent Tumkaya, Kerimali Akyildiz, Sinan Saral & Adnan Yilmaz. (2023) Agomelatine on cisplatin-induced nephrotoxicity via oxidative stress and apoptosis. Naunyn-Schmiedeberg's Archives of Pharmacology.
Crossref
Crossref
Erika Cecon, Jean A. Boutin & Ralf Jockers. (2023) Molecular Characterization and Pharmacology of Melatonin Receptors in Animals. Receptors 2:2, pages 127-147.
Crossref
Crossref
Mohammad Tobeiha, Ameneh Jafari, Sara Fadaei, Seyed Mohammad Ali Mirazimi, Fatemeh Dashti, Atefeh Amiri, Haroon Khan, Zatollah Asemi, Russel J. Reiter, Michael R. Hamblin & Hamed Mirzaei. (2022) Evidence for the Benefits of Melatonin in Cardiovascular Disease. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Ayman M. Mahmoud, Omnia A.M. Abd El-Ghafar, Mohammed A. Alzoghaibi & Emad H.M. Hassanein. (2021) Agomelatine prevents gentamicin nephrotoxicity by attenuating oxidative stress and TLR-4 signaling, and upregulating PPARγ and SIRT1. Life Sciences 278, pages 119600.
Crossref
Crossref
Aneta Ostróżka-Cieślik & Barbara Dolińska. (2020) The Role of Hormones and Trophic Factors as Components of Preservation Solutions in Protection of Renal Function before Transplantation: A Review of the Literature. Molecules 25:9, pages 2185.
Crossref
Crossref
Hatice Aygun & Serdar Savas Gul. (2018) Effects of melatonin and agomelatine on doxorubicin induced anxiety and depression-like behaviors in rats. Medical Science and Discovery 5:7, pages 253-259.
Crossref
Crossref
Eliška Skořepová, Daniel Bím, Michal Hušák, Jiří Klimeš, Argyro Chatziadi, Luděk Ridvan, Tereza Boleslavská, Josef Beránek, Pavel Šebek & Lubomír Rulíšek. (2017) Increase in Solubility of Poorly-Ionizable Pharmaceuticals by Salt Formation: A Case of Agomelatine Sulfonates. Crystal Growth & Design 17:10, pages 5283-5294.
Crossref
Crossref
Jin-Yi Hyeon, Eun-Young Choi, So-Hui Choe, Hae Ryoun Park, Jeom-Il Choi, In Soon Choi & Sung-Jo Kim. (2017) Agomelatine, a MT1/MT2 melatonergic receptor agonist with serotonin 5-HT2C receptor antagonistic properties, suppresses Prevotella intermedia lipopolysaccharide-induced production of proinflammatory mediators in murine macrophages. Archives of Oral Biology 82, pages 11-18.
Crossref
Crossref
Eliška Skořepová, Michal Hušák, Luděk Ridvan, Marcela Tkadlecová, Jaroslav Havlíček & Michal Dušek. (2016) Iodine salts of the pharmaceutical compound agomelatine: the effect of the symmetric H-bond on amide protonation. CrystEngComm 18:24, pages 4518-4529.
Crossref
Crossref
Wen-Juan Liang, Yun-Bao Ma, Chang-An Geng, Xiao-Yan Huang, Hong-Bo Xu, Xue-Mei Zhang & Ji-Jun Chen. (2015) Paeoveitols A–E from Paeonia veitchii. Fitoterapia 106, pages 36-40.
Crossref
Crossref
Jin-Seong Lee, Sung-Gon Kim, Ji-Hoon Kim, Woo-Young Jung & Ji-Hoon Park. (2015) Melatonin in Psychiatric Disorders. Sleep Medicine and Psychophysiology 22:1, pages 5-10.
Crossref
Crossref
Mona Dastgheib & Leila Moezi. (2014) Acute and chronic effects of agomelatine on intravenous penthylenetetrazol-induced seizure in mice and the probable role of nitric oxide. European Journal of Pharmacology 736, pages 10-15.
Crossref
Crossref
Frederick R. Taylor, Stephen H. Landy & Robert G. Kaniecki. (2013) Abstracts and Citations. Headache: The Journal of Head and Face Pain 53:8, pages 1367-1377.
Crossref
Crossref
Ying-Hui Wu, Jeanine Ursinus, Jiang-Ning Zhou, Frank A.J.L. Scheer, Bao Ai-Min, Ralf Jockers, Joop van Heerikhuize & Dick F. Swaab. (2013) Alterations of melatonin receptors MT1 and MT2 in the hypothalamic suprachiasmatic nucleus during depression. Journal of Affective Disorders 148:2-3, pages 357-367.
Crossref
Crossref
I. Shcherbakova. (2013) A Drug Mystery of Heterocycles: Various Molecules for One Target or One Compound for Multiple Targets?. Chemistry of Heterocyclic Compounds 49:1, pages 2-18.
Crossref
Crossref
Riccardo Guglielmo, Giovanni Martinotti, Massimo Di Giannantonio & Luigi Janiri. (2013) A Possible New Option for Migraine Management. Clinical Neuropharmacology 36:2, pages 65-67.
Crossref
Crossref
Yueqing Hu, Jing Zhu, King H. Chan & Yung H. Wong. (2013) Development of substituted N-[3-(3-methoxylphenyl)propyl] amides as MT2-selective melatonin agonists: Improving metabolic stability. Bioorganic & Medicinal Chemistry 21:2, pages 547-552.
Crossref
Crossref
Antonio Cutando, Jose Aneiros-Fernández, Antonio López-Valverde, Salvador Arias-Santiago, Jose Aneiros-Cachaza & Russel J. Reiter. (2011) A new perspective in Oral health: Potential importance and actions of melatonin receptors MT1, MT2, MT3, and RZR/ROR in the oral cavity. Archives of Oral Biology 56:10, pages 944-950.
Crossref
Crossref
Indrajit Chowdhury & Saumen Maitra. 2011. Melatonin in the Promotion of Health, Second Edition. Melatonin in the Promotion of Health, Second Edition
1
60
.
Ludwig Vincent, William Cohen, Philippe Delagrange, Jean A. Boutin & Olivier Nosjean. (2010)
Molecular and cellular pharmacological properties of 5‐methoxycarbonylamino‐
N
‐acetyltryptamine (MCA‐NAT): a nonspecific MT3 ligand
. Journal of Pineal Research 48:3, pages 222-229.
Crossref
Crossref
Luis San & Belén Arranz. (2010) Agomelatina: un nuevo enfoque antidepresivo para una remisión de calidad. Revista de Psiquiatría y Salud Mental 3, pages 15-20.
Crossref
Crossref
Lucia Fatima Sobral Sampaio. (2009) An unexpected effect of 5‐MCA‐NAT in chick retinal development. International Journal of Developmental Neuroscience 27:6, pages 511-515.
Crossref
Crossref
Pilar Alarma‐Estrany, Almudena Crooke & Jesús Pintor. (2009) 5‐MCA‐NAT does not act through NQO2 to reduce intraocular pressure in New‐Zealand white rabbit. Journal of Pineal Research 47:2, pages 201-209.
Crossref
Crossref
D. G. Ahern, J. C. Morrison & C. N. Filer. (2008) Tritiation of melatonin by several methods. Journal of Radioanalytical and Nuclear Chemistry 279:1, pages 3-6.
Crossref
Crossref
Josephine Arendt & Debra Skene. 2008. Handbook of Sleep Disorders, Second Edition. Handbook of Sleep Disorders, Second Edition
207
221
.
Jian-hua Yan, Hao-ran Su, Jean A Boutin, M Pierre Renard & Ming-wei Wang. (2008) High-throughput screening assay for new ligands at human melatonin receptors. Acta Pharmacologica Sinica 29:12, pages 1515-1521.
Crossref
Crossref
Luis San & Belen Arranz. (2020) Agomelatina: un fármaco nuevo con acción antidepresiva que afecta a los sistemas melatonérgico y serotonérgico. European psychiatry (Ed. Española) 15:8, pages 375-381.
Crossref
Crossref
Luis San & Belen Arranz. (2020) Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. European Psychiatry 23:6, pages 396-402.
Crossref
Crossref
Nobuo Suzuki, Masanori Somei, Kei-Ichiro Kitamura, Russel J. Reiter & Atsuhiko Hattori. (2008) Novel bromomelatonin derivatives suppress osteoclastic activity and increase osteoblastic activity: implications for the treatment of bone diseases. Journal of Pineal Research 44:3, pages 326-334.
Crossref
Crossref
Prabal K. Chatterjee. (2007) Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review. Naunyn-Schmiedeberg's Archives of Pharmacology 376:1-2, pages 1-43.
Crossref
Crossref
Y. Touitou. (2007) Troubles du sommeil et hypnotiques. Annales Pharmaceutiques Françaises 65:4, pages 230-238.
Crossref
Crossref
Colleen A. McClung. (2007) Circadian genes, rhythms and the biology of mood disorders. Pharmacology & Therapeutics 114:2, pages 222-232.
Crossref
Crossref
Seithikurippu R Pandi-Perumal, Venkatramanujan Srinivasan, D Warren Spence & Daniel P Cardinali. (2007) Role of the Melatonin System in the Control of Sleep. CNS Drugs 21:12, pages 995-1018.
Crossref
Crossref